Log in to save to my catalogue

Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-po...

Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-po...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_03468337v1

Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer

About this item

Full title

Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer

Publisher

New York: Springer US

Journal title

Breast cancer research and treatment, 2022-01, Vol.191 (1), p.191-207

Language

English

Formats

Publication information

Publisher

New York: Springer US

More information

Scope and Contents

Contents

Purpose
A major question when treating HR+/HER2− metastatic breast cancer (MBC) is whether early introduction of chemotherapy (CT) increases endocrine resistance. We aimed to describe progression-free survival (PFS) under first endocrine therapy (ET) depending on whether given before or after CT in a large nationwide cohort, in the pre-CDK era.<...

Alternative Titles

Full title

Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_03468337v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_03468337v1

Other Identifiers

ISSN

0167-6806

E-ISSN

1573-7217

DOI

10.1007/s10549-021-06382-6

How to access this item